Gordon J. Freeman

Gordon J. Freeman, Ph.D., is Professor of Medicine at Dana-Farber Cancer Institute and Harvard Medical School, where he also holds an adjunct appointment in the Department of Immunology and Virology. He is internationally recognized for discovering the PD-L1 and PD-L2 proteins and demonstrating their roles as ligands for the PD-1 receptor on T cells. In 2000, Dr. Freeman published landmark research in the Journal of Experimental Medicine showing that when PD-L1 binds to PD-1 receptors on T cells, it activates an inhibitory pathway that suppresses immune responses. Crucially, he demonstrated that PD-L1 is highly expressed on many solid tumors and hematologic malignancies, enabling these cancers to evade immune attack. His discovery that blocking the PD-1/PD-L1 interaction could unleash T-cell activity against cancer established the scientific foundation for immune checkpoint blockade therapy. This work directly led to FDA approval of PD-1/PD-L1 inhibitors including nivolumab (Opdivo, 2014), pembrolizumab (Keytruda, 2014), and atezolizumab (Tecentriq, 2016), now approved for over twenty-five cancer types. Beyond PD-1/PD-L1, Freeman has systematically characterized the B7:CD28 family of costimulatory and coinhibitory molecules. Working closely with his wife and long-time collaborator Arlene H. Sharpe, he elucidated how B7-1 (CD80) and B7-2 (CD86) regulate T-cell activation through CD28 and CTLA-4 interactions. His research identified major pathways controlling immune responses—both inhibitory (PD-L1/PD-1, B7-2/CTLA-4) and stimulatory (B7-2/CD28)—providing critical translational insights for developing immunotherapies for cancer, autoimmune diseases, and transplant rejection. Freeman has published over 400 scientific papers and holds more than 90 U.S. patents on immunotherapies. He is a Highly Cited Researcher (Thomson Reuters, 2002 onwards) and 2016 Citation Laureate. He was elected to the National Academy of Sciences (2022), National Academy of Inventors, and American Academy of Arts and Sciences. His honors include the inaugural Gretener-Thürlemann Prize ($625,000, 2025), Hamburg Award (2024), AACR-CRI Lloyd J. Old Award (2024), Warren Alpert Foundation Prize (2017), and William B. Coley Award (2014).

Gordon J. Freeman博士是Dana-Farber癌症研究所和哈佛大学医学院医学教授,同时在免疫学和病毒学系担任兼职教授。他因发现PD-L1和PD-L2蛋白并证明它们作为T细胞PD-1受体配体的作用而享誉国际。 2000年,Freeman博士在Journal of Experimental Medicine发表里程碑研究,证明PD-L1与T细胞PD-1受体结合时激活抑制性通路,抑制免疫反应。关键的是,他证明PD-L1在多种实体瘤和血液系统恶性肿瘤上高表达,使这些癌症逃避免疫攻击。他发现阻断PD-1/PD-L1相互作用可释放T细胞对癌症的活性,为免疫检查点阻断疗法奠定了科学基础。这项工作直接促成PD-1/PD-L1抑制剂获FDA批准,包括nivolumab (Opdivo, 2014)、pembrolizumab (Keytruda, 2014) 和atezolizumab (Tecentriq, 2016),现已批准用于25+种癌症类型。 除PD-1/PD-L1外,Freeman系统研究了B7:CD28家族共刺激和共抑制分子。他与妻子及长期合作者Arlene H. Sharpe密切合作,阐明B7-1 (CD80) 和B7-2 (CD86) 如何通过CD28和CTLA-4相互作用调节T细胞活化。他的研究识别了控制免疫反应的主要通路——包括抑制性通路(PD-L1/PD-1、B7-2/CTLA-4)和刺激性通路(B7-2/CD28)——为开发癌症、自身免疫疾病和移植排斥免疫治疗提供了关键转化见解。 Freeman发表400+篇科学论文,持有90+项美国免疫治疗专利。他是高被引学者(Thomson Reuters, 2002年至今)和2016年引文桂冠奖获得者。2022年当选美国国家科学院院士,同时为国家发明家科学院和美国艺术与科学院院士。他的荣誉包括首届Gretener-Thürlemann奖($625,000, 2025)、Hamburg奖(2024)、AACR-CRI Lloyd J. Old奖(2024)、Warren Alpert基金会奖(2017)和William B. Coley奖(2014)。